Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
432 studies found for:    "Expanded Access" [STUDY-TYPES]
Show Display Options
RSS Create an RSS feed from your search for:
"Expanded Access" [STUDY-TYPES]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 No longer available Compassionate Use Treatment for a Single Patient With a Custom Made Branched/Fenestrated Endovascular Device for the Treatment of Complex Abdominal Aortic Aneurysm
Condition: Complex Abdominal Aortic Aneurysm
Intervention: Device: Fenerated AAA Endovascular Graft with H&L-B One Shot Introduction System
2 Available An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors
Condition: Hemophilia A
Intervention: Biological: Emicizumab
3 Available Axicabtagene Ciloleucel Expanded Access Study
Conditions: Relapsed/Refractory Transplant Ineligible Diffuse Large B Cell Lymphoma;   Relapsed/Refractory Transplant Ineligible Primary Mediastinal B Cell Lymphoma;   Relapsed/Refractory Transplant Ineligible Transformed Follicular Lymphoma
Intervention: Biological: Axicabtagene Ciloleucel
4 Available An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Condition: Graft-versus-host Disease (GVHD)
Intervention: Drug: Ruxolitinib
5 Available Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC
Conditions: Leukemia;   Bone Marrow Failure Syndrome;   Immunodeficiencies
Intervention: Device: Apha/beta T and CD19+ cell depletion using CliniMACS device
6 Available Expanded Access to VAL-083
Condition: Cancer
Intervention: Drug: VAL-083
7 Available Expanded Access Program for ONC201 to Treat Recurrent Histone H3 Mutant Glioma
Condition: Glioma
Intervention: Drug: ONC201
8 Available Single Patient, Compassionate Use of MARGETUXIMAB for the Treatment of HER2+ Metastatic Breast Cancer
Conditions: HER2-positive Breast Cancer;   Neoplasm Metastasis
Intervention:
9 Temporarily not available Use of Domperidone for Treatment of Upper Gastrointestinal Disorders
Condition: Gastroparesis
Intervention: Drug: Domperidone
10 Available Lorlatinib - PF-06463922
Condition:
Intervention: Drug: Lorlatinib
11 Available Inotuzumab Ozogamicin - PF-05208773
Condition:
Intervention: Drug: Inotuzumab Ozogamicin
12 Available Expanded Access for Nivolumab (Opdivo)
Condition: Pediatric Cancer
Intervention: Biological: Nivolumab
13 Available Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Biological: Elotuzumab
14 Available Compassionate Use Program For Subcutaneous (SC) Belimumab
Condition: Systemic Lupus Erythematosus
Intervention: Drug: SC belimumab 200 mg
15 Available Expanded Access to Glecaprevir/ Pibrentasvir
Condition: Hepatitis C Virus Infection
Interventions: Drug: glecaprevir;   Drug: pibrentasvir
16 Available Expanded Access to ABT-414
Condition: Cancer
Intervention: Drug: ABT-414
17 Available Expanded Treatment Protocol in Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Intervention: Genetic: CTL019
18 Available Expanded Access to Veliparib
Condition: Cancer
Intervention: Drug: Veliparib
19 Available Expanded Access to Venetoclax
Conditions: Chronic Lymphocytic Leukemia (CLL);   Multiple Myeloma;   Acute Myeloid Leukemia (AML);   Non-Hodgkin's Lymphoma
Intervention: Drug: Venetoclax
20 Available An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)
Condition: FLT3-mutated Acute Myeloid Leukemia
Intervention: Drug: Midostaurin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.